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Abstract
Objective: To evaluate the effectiveness and safety of polyunsaturated fatty acids for the treatment of the
premenstrual syndrome (PMS) using a graded symptom scale and to assess the effect of this treatment on basal
plasma levels of prolactin and total cholesterol.
Methods: A randomized, double-blind, placebo-controlled study was conducted with 120 women with PMS
divided into three groups and treated with 1 or 2 grams of the medication or placebo. Symptoms were recorded
over a 6-month period using the Prospective Record of the Impact and Severity of Menstruation (PRISM) calendar.
Total cholesterol and prolactin levels were measured. Analysis of variance (ANOVA), Pearson’s chi-square test,
Wilcoxon’s nonparametric signed-rank test for paired samples and the Mann-Whitney nonparametric test for
independent samples were used in the statistical analysis.
Results: There were no differences in age, marital status, schooling or ethnicity between the groups. In the group
treated with 1 gram of the medication, a significant reduction was found when the median PRISM score recorded
in the luteal phase at baseline (99) was compared with the median score recorded in the 3
rd month (58) and in
the 6
th month of evaluation (35). In the 2-gram group, these differences were even more significant (baseline
score: 98; 3
rd month: 48; 6
th month: 28). In the placebo group, there was a significant reduction at the 3
rd but not
at the 6
th month (baseline: 96.5; 3
rd month: 63.5; 6
th month: 62). The difference between the phases of the
menstrual cycle was greater in the 2-gram group compared to the group treated with 1 gram of the medication.
There were no statistically significant differences in prolactin or total cholesterol levels between baseline values and
those recorded after six months of treatment.
Conclusion: The difference between the groups using the medication and the placebo group with respect to the
improvement in symptomatology appears to indicate the effectiveness of the drug. Improvement in symptoms
was higher when the 2-gram dose was used. This medication was not associated with any changes in prolactin or
total cholesterol levels in these women.
Background
The premenstrual syndrome (PMS) was first described in
1931 by Frank and Horney, who speculated on the possi-
ble physiopathological origins of the condition and on
some forms of treatment [1]. PMS is understood as the set
of somatic, affective, psychic and behavioral manifestations
that commonly occur in the period preceding menstrua-
tion, the postovulatory phase of the menstrual cycle [2]. In
general, these symptoms appear around 10-12 days prior
to menstruation and disappear abruptly when bleeding
begins. Following a remission period, the symptoms
invariably return on a cyclic, recurrent basis and may be
debilitating in some cases [3].
PMS is part of a wide spectrum of manifestations
related to the premenstrual and menstrual phases.
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clinical signs and symptoms such as mastalgia and pain
in their lower limbs, but who have none of the symp-
toms that cause psychic suffering. At the other extreme
are the women who suffer from premenstrual dysphoric
disorder (PMDD). According to the American Psychia-
tric Association, this is the term currently used to define
the most severe forms of PMS that require psychiatric
intervention due to the severity of the patient’sc l i n i c a l
condition, which may include deep depression and sui-
cide/homicide attempts [4]. For a diagnosis of PMDD, a
defined set of symptoms must be prospectively docu-
mented and shown to provoke significant functional
disability [5].
The prevalence of PMS is high. Up to 80% of women
of reproductive age may suffer from physical or emo-
tional symptoms [6]. Around 80-95% of women with a
biphasic menstrual cycle are estimated to suffer from at
least one of the symptoms of PMS in the premenstrual
phase of the cycle and, of these, around 35% have symp-
toms severe enough to affect their routine activities. In
general, symptoms are sufficiently intense for the condi-
tion to be classified as premenstrual dysphoric disorder
in around 3-15% of PMS patients [1]. The negative
effect of symptoms on the woman’s routine activities
and quality of life may be significant [7], in addition to
the repercussions on economic costs resulting predomi-
nantly from a reduction in productivity [8,9]. The
instability resulting from women’s reproductive cycles
has even been used to justify denying them equal access
to education and jobs [10].
The physiopathology of PMS has yet to be fully clari-
fied and may include the effect of estrogens, the effect of
progesterone on neurotransmitters such as serotonin,
opioids, catecholamines and GABA [11], a relative reduc-
tion in cortisol, suprarenal dysfunction and abnormalities
in the hormonal regulation of water and salt in the body,
a deficiency in the modulatory effects of gonadotrophins
and their direct effect on other tissues, vitamin B6 defi-
ciency, increased prolactin levels or increased sensitivity
to the effects of prolactin [12], insulin resistance [13],
hypersensitivity to endogenous hormones, a physiological
reduction in endogenous opioid peptides during the
menstrual cycle [14,15], dysfunction in the circadian pat-
tern of melatonin secretion, intracytoplasmic alterations
in electrolytes (calcium, zinc, copper and sodium), psy-
chosomatic effects and prostaglandin E1 deficiency [16].
Cyclic changes in many target tissues and fluctuations in
ovarian steroid levels are physiological phenomena that
occur in women who ovulate. In patients with PMS,
these physiological changes may be more intense.
Several characteristics of PMS are similar to the effects
produced by the injection of prolactin [12]. Some women
with the premenstrual syndrome have elevated prolactin
levels, but in most the prolactin concentrations are nor-
mal. Some women with PMS have high levels of prolactin,
but often they are normal. It is possible that women with
the syndrome are abnormally sensitive to normal amounts
of prolactin. One possibility is that women with the syn-
drome are abnormally sensible to normal quantities of
prolactin. There is evidence that prostaglandin E1, derived
from dietary essential fatty acids, is able to attenuate the
biologic actions of prolactin and that in the absence of
prostaglandin E1 prolactin has exaggerated effects. There
are evidences that prostaglandin E1, derived from essential
fatty acids from diet, is able to attenuate the biological
actions of prolactin and that, in the absence of prolactin,
the prostaglandin E1 presents exacerbated effects.
Attempts were made, therefore, to treat women who had
the premenstrual syndrome with gamma-linolenic acid, an
essential fatty acid precursor of prostaglandin E1. The
gamma-linolenic acid is a precursor of essential fatty acids
from prostaglandin E1. The nutrients known for increas-
ing the metabolism of essential fatty acids intoGamma-
linolenic acid is found in human, but not cows’, milk and
in evening primrose oil, the preparation used in these stu-
dies. prostaglandins E1 are magnesium, pyridoxine, zinc,
niacin and ascorbic acid. The clinical success obtained
with some of these nutrients can, at least in part, be due to
their effects on the metabolims of essential fatty acids [12].
The clinical success obtained with some of these nutrients
may in part relate to their effects on essential fatty acid
metabolism.
Polyunsaturated fatty acids are known to exert a modu-
lating effect on cell membrane structure, participating
directly on prostaglandin formation and acting in the reg-
ulation of cholesterol synthesis and transport and in the
control of cell membrane permeability. Essential fatty
acids and their derivatives exert various biological effects
that may play a relevant role in several physiological and
pathological processes [17]. Prostaglandins, on the other
hand, are potent biochemical mediators that are involved
in the regulation of the central nervous system, hydroelec-
trolytic homeostasis, gastrointestinal function and uterine
contractility [18]. The principal symptoms of PMS may be
a consequence of disorders in organ functions regulated
by prostaglandins [12,19]. Women with PMS may be
abnormally sensitive to normal levels of prolactin [12] and
this phenomenon may be related to low PGE1 levels.
Oleic, linoleic, and gamma-linolenic acids, which are
polyunsaturated fatty acids, are not produced in the
body and are only available through dietary intake,
where they are present in small quantities. In the body,
these acids lead to the formation of 1-series prostaglan-
dins, particularly PGE1.
The most common classification of PMS divides the
syndrome into four groups (A, H, C and D), referring to
anxiety, water and salt retention (hydric), cephalea and
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minant symptoms [2,20]. Diagnosis can only be made
when the patient has spontaneous menstrual cycles. Up
to the present moment, none of the symptoms or altera-
tions in hormone or biochemical measurements has
been found to be pathognomonic. The diagnostic meth-
ods most commonly used in clinical trials are based on
questionnaires and diaries applied by the examiner or by
the patient herself, the most universally widely used tool
being the Prospective Record of the Impact and Severity
of Menstruation (PRISM) calendar, developed in 1985
by Reid and Yen [21], which consists of 26 domains that
are evaluated and quantified daily by the patient herself
in accordance with the severity of her symptoms.
Treatment of this disorder is as controversial as its
physiopathology and includes the use of hormonal con-
traceptives, pyridoxine, nonsteroidal antiinflammatory
drugs, diuretics, calcium channel blockers, acupuncture,
vitamins A and E and GnRH analogs, among others.
More recently, some authors have recommended the
use of essential fatty acids as representing a valid thera-
peutic option for women with PMS [12,20,22,23]. These
substances do not appear to provoke any hormonal or
biochemical disruptions in women, hence may be con-
sidered safe. Nevertheless, no consensus based on strong
scientific evidence has yet been reached with respect to
the treatment of PMS.
Therefore, the objectives of the present study were to
compare the effectiveness and safety of six treatment
cycles with two different doses of essential fatty acids on
the severity of PMS symptoms as evaluated clinically
and with the use of a graded symptom scale, and to
assess the effect of this treatment on basal plasma levels
of prolactin and total cholesterol in the secretory phase
of the menstrual cycle.
Methods
A randomized, double-blind, placebo-controlled study
was performed using two different doses of essential
fatty acids and a placebo for the treatment of women
with PMS over six consecutive cycles. Each woman par-
ticipated in the trial for a total of 240 days, and received
medication on 180 days.
For the sample size calculation, the results of a pilot
evaluation were used, considering the parameter of
mean prolactin level at six months after using 2 g of
essential fatty acids or placebo, respectively 9.32 and
10.8, with an expected standard deviation of 5.7. Using
a confidence level of 95% and a power of 80%, 38 sub-
jects were estimated to be necessary in each group.
Then 120 patients were planned to be enrolled, 40 in
each group.
A total of 120 patients of reproductive age with regu-
lar menstrual cycles, who fulfilled the diagnostic criteria
for the definition of PMS or PMDD and who were
attending the outpatient clinic of the institution between
June 2004 and January 2008, were studied prospectively.
Inclusion criteria consisted of: not having used specific
treatments for at least three cycles, being between 16
and 49 years of age, having completed at least primary
education and being in a good state of health. Women
who were pregnant or who wished to become pregnant,
those who had used hormones in the previous three
months, women with any clinical conditions such as
cancer, thromboembolic, infectious, vascular, hepatic,
cardiac, renal, neurological, psychiatric or endocrine dis-
eases (confirmed clinically and/or by laboratory tests),
chronic alcoholics, smokers, drug users and those in
regular use of any medication were excluded from
the trial.
Patients interested in participating in the study were
given a copy of the informed consent form, which was
then read and signed by each woman prior to admis-
sion to the study. Following enrollment, the partici-
pant’s medical history was recorded and she was
submitted to a physical examination. The patient
received instructions and was asked to return after she
had completed the PRISM calendar for one full month
s ot h a tt h ed a t af r o mt h ef i r s tm o n t hc o u l db ea n a -
lyzed, after which she received a new calendar to be
filled out over one more month. After filling out the
calendar for the second month, the data from the two
calendars were analyzed together to determine whether
t h ed i a g n o s t i cc r i t e r i at h a td e f i n eP M Sw e r ep r e s e n t :a
higher concentration of symptoms in the premenstrual
and menstrual phases with an improvement or remis-
sion following menstruation that continued throughout
the follicular phase of the following cycle. If diagnosis
was confirmed, the patient was then randomized to
one of three treatment groups, received a new PRISM
calendar and the assigned medication.
The PRISM calendar consists of a list of symptoms
(23 physical symptoms). The patient is asked to give a
score of 0 to 3 points for each symptom on each indivi-
dual day as follows: 0 if she has not experienced that
particular symptom on that specific day; 1 if the symp-
tom was mild; 2 if the symptom was moderate; and 3 if
the symptom was severe. At the end of each month, the
scores awarded to all the symptoms were added, with
the scores referring to the follicular phase of the cycle
being separated from those referring to the luteal phase.
Patients in whom the total score for symptomatology
increased by at least 30% between the follicular and
luteal phases of the cycle were considered to have PMS.
Quantification of the points in the two phases also
served to evaluate therapeut i cr e s p o n s et ot h es t u d y
medication at the different evaluation moments: at base-
line and after 3 and 6 months of treatment.
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gelatin capsules containing the active ingredient (each 1-
gram capsule contained a mean of 210 mg of gamma
linolenic acid, 175 mg of oleic acid, 345 mg of linoleic
acid, 250 mg of other polyunsaturated acids and 20 mg
of vitamin E); or containing placebo (1 gram of mineral
oil). The capsules were packaged as follows:
1) Packages of two blister packs, each containing
15 capsules: in one blister pack the capsules con-
tained 1 gram of the active ingredient and in the
other the capsules contained the placebo. These
packages were given to the patients randomized to
Group A, the 1-gram dose group.
2) Packages of two blister packs, each with 15 cap-
sules containing 1 gram of the active ingredient,
which were given to the patients randomized to
Group B, the 2-gram dose group.
3) Packages of two blister packs, each with 15 cap-
sules containing only placebo. These were given to
the patients randomized to Group C, the placebo
group.
Mineral oil was chosen as the placebo since it has
physical properties similar to those of the study medica-
tion and since at the doses used in this study it is not
associated with any significant side effects.
The patients were then distributed randomly to one of
the three study groups and instructed to take two cap-
sules, one from each of the two blister packs in the
packet, orally every day at bedtime, preferably between
8 and 10 pm, for fifteen days, beginning on the fifteenth
day of the cycle. The same schedule was repeated
monthly throughout the study and the PRISM calendar
was filled out daily. If the patient forgot to take the
medication for one or more consecutive days, the cap-
sules that were not taken were to be left in the blister
pack and the capsule for the following day taken in
accordance with the schedule. All the blister packs,
whether empty or still containing capsules, were to be
returned to the investigator at each visit. Treatment was
to continue as planned, uninterruptedly for the six-
month study period. Blood samples were taken for ana-
lysis prior to treatment (baseline) and at three and six
months of treatment.
The patients were allocated to the treatment groups in
equal numbers based on a previously prepared, compu-
ter-generated randomization list. The random numbers
were assigned sequentially in the order in which the
patients were screened and found to be eligible for
inclusion. A sealed, opaque, sequentially numbered
envelope was allocated to each patient, thus ensuring
the concealment of the randomization procedure. These
envelopes contained the identification of the study
group (A, B or C) to which the patient was allocated
and corresponded to a package containing the medica-
tion for that respective group. The key regarding which
medication had been allocated to each group was only
opened at the end of the study. The appearance and the
packaging of the capsules containing the active ingredi-
ent and those containing the placebo were identical. At
each visit to the clinic, the patients were questioned
regarding their compliance with the study protocol. The
returned packages of medication were inspected, the ori-
ginal diary cards were collected and the data transcribed
to the clinical evaluation form.
Patients were also given a list of the drugs considered
contraindicated during the study period, since it was
believed that they could interfere with the effects of the
study drug. These medications included any other ara-
chidonic acid derivatives, hormonal or nonsteroidal anti-
inflammatory drugs, steroids or tricyclic antidepressants.
Safety was evaluated according to any changes found
at the physical and gynecological examinations (includ-
ing cervical smear and breast examination), in laboratory
tests (including hematology and serum biochemistry,
with particular emphasis on total cholesterol) and in the
occurrence of adverse events. Levels of seric prolactin
were measured for all patients in the study. The princi-
pal investigator of the study established standard operat-
ing procedures in conformance with global regulatory
requirements guaranteeing appropriate reporting of
safety data.
The patient could be discontinued from the study
prior to completing the protocol for any one of the fol-
lowing reasons: in the occurrence of an adverse event,
in accordance with the patient’s wishes or if she became
lost to follow-up. Under any of these circumstances, the
patient was discontinued and the reason for her discon-
tinuation was recorded. She was not substituted, but the
data collected up to her discontinuation were used
under the intention to treat approach of analysis.
Data were entered onto an Excel spreadsheet and then
analyzed using the SPSS software program, version 13.
A significance level of 5% was used for all the statistical
tests. Initially, analysis of variance (ANOVA) for quanti-
tative variables was used to compare the characteristics
of the women in the three groups, while Pearson’sc h i -
square test was used for qualitative variables. To com-
pare PRISM scores, the median score was used together
with the respective 1
st and 3
rd quartiles, and the groups
were compared using Wilcoxon’s nonparametric signed-
rank test for paired samples and the Mann-Whitney
nonparametric test for independent samples.
The Institutional Review Board of the Health Sciences
Center, Federal University of Pernambuco approved the
study protocol. Confidentiality with respect to the
source of data was guaranteed and each woman was
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informed consent form. The study drug was supplied
free of charge by Hebron Farmaceutica,w h i c hw a sn o t
involved in any way with the study design, analysis or
interpretation of the results.
Results
Of the 120 women randomized, 116 were analyzed at
the end of the study period. One patient in Group A
was excluded from the study due to hyperprolactinemia
and one patient in Group B due to thyroid dysfunction
(samples were collected at the beginning of the study
but the results were known only after enrollment, before
starting medication). Two patients were discontinued in
the placebo group because they were found to be using
antidepressants. Figure 1 illustrates the flow of patients
through the study. There was no statistically significant
difference between the groups with respect to age, mari-
tal status, schooling or ethnicity (Table 1).
A ss h o w ni nT a b l e2 ,t h eo v e r a l lm e d i a nP R I S M
score in the follicular phase and that found in the
luteal phase were significantly different, with a higher
median score in the luteal phase at all evaluation
moments and in all groups, showing that symptoms in
the patients in the study were in fact more intense
during the luteal phase. There were no statistically sig-
nificant differences in the overall median PRISM score
in the first month (untreated cycle) between the three
groups.
By the third treatment month, a significant change had
occurred in the median overall PRISM score, both in the
follicular and in the luteal phases, in the groups receiving
either one of the two doses of the study medication
(Groups A and B). A reduction was found in the scores at
the 3
rd and 6
th months of follow-up compared to the base-
line score.
In the placebo group, a statistically significant reduc-
tion occurred in the median PRISM score at the 3
rd
  214 women invited 
120 women with PMS included in 
the study and randomized 
94 women excluded due to 
inclusion/exclusion criteria  
Group A 
1g FA 
40 women 
Group B 
2g FA 
40 women 
Group C 
Placebo 
40 women 
39 women 
analyzed 
39 women 
analyzed 
38 women 
analyzed 
1 excluded due to   
hyperprolactinemia 
1 excluded due to  
thyroid dysfunction 
2 excluded due to use 
of antidepressant drugs
Figure 1 Flowchart of subjects in the study.
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however, at the 6
th month of follow-up this difference
was no longer statistically significant. The reduction
found at the 3
rd month, although statistically significant,
was considerably less than the reduction found at the
3
rd month of follow-up in the groups treated with either
1 or 2 grams of the medication.
When the overall PRISM score was evaluated from the
3
rd month onwards, a statistically significant difference
was found in all the groups. However, the reduction in
the median score between the phases of the menstrual
cycle was greater in the 2-gram group compared either
to the 1-gram group or the placebo group. This differ-
ence was also confirmed in the comparison between the
placebo group and the 1-gram group.
As shown in Table 3, no significant changes were
found in mean prolactin or total cholesterol when levels
at baseline were compared with those at the end of the
study.
During the study, one patient reported mild abdom-
inal discomfort during treatment with 1 gram of the
medication; however, this complaint disappeared sponta-
neously in the second month of treatment. One patient
in Group B (2 grams) had a delay of 11 days in her
menstrual period; however, ß-hCG was negative. Two
patients in the placebo group had mild, transitory epi-
sodes of diarrhea but they had no complaint of diarrhea
during the menstrual phase.
Discussion
In the present study, the administration of 1 or 2 grams
of essential fatty acids to patients with PMS resulted in
a significant decrease in symptom scores, as evaluated
using the PRISM calendar. The three groups analyzed
Table 1 Characteristics of the study population
Characteristics Groups
A (1 g) B (2 g) C (Placebo)
Age (mean ± SD)
Δ 33.0 ± 6.6 32.4 ± 6.1 32.7 ± 6.3
Marital status - n (%) *
Single 14 (35.9) 15 (38.5) 16 (42.1)
Married 22 (56.4) 21 (53.8) 21 (55.3)
Other 03 (7.7) 03 (7.7) 01 (2.6)
Schooling - n (%) *
Primary 16 (41.0) 19 (48.7) 19 (50.0)
High school 20 (51.3) 17 (43.6) 17 (44.7)
University 03 (7.7) 03 (7.7) 02 (5.3)
Ethnicity - n (%) *
White 05 (12.8) 07 (17.9) 07 (18.4)
Non-white 34 (87.2) 32 (82.1) 31 (81.6)
Total 39 39 38
Δ Test ANOVA (p = 0.926).
* Pearson’s chi-square test (marital status: p = 0.861; schooling: p = 0.925;
ethnicity: p = 0.761).
Table 2 Total PRISM score according to treatment group, evaluation moment and phase of the menstrual cycle
Period Treatment Groups Difference between groups p-value*
A (1 g) B (2 g) C (Placebo)
Median (P25 -P 75) Median (P25 -P 75) Median (P25 -P 75)
Pretreatment
Follicular 29 (19 - 63) 27 (17 - 37) 28.5 (19 - 33) A X B: 0.2629
Luteal 99 (87 - 162) 98 (82 - 123) 96.5 (89 - 117) A X C: 0.3130
Difference 77 (61 - 94) 73 (51 - 84) 74 (49 - 88) B X C: 0.9878
p-value
Δ < 0.001 < 0.001 < 0.001
3 months
Follicular 17 (11 - 38) 21 (15 - 25) 25.5 (18 - 31) A X B: 0.0017
Luteal 58 (42 - 79) 48 (41 - 61) 88.5 (78 - 109) A X C: 0.0001
Difference 41 (26 - 50) 27 (20 - 34) 63.5 (48 - 79) B X C: <0.001
p-value
Δ < 0.001 < 0.001 < 0.001
6 months
Follicular 08 (05 - 28) 09 (07 - 12) 25 (16 - 31) A X B: 0.0029
Luteal 35 (31 - 56) 28 (24 - 35) 89 (74 - 105) A X C: <0.001
Difference 27 (18 - 33) 18 (12 - 23) 62 (41 - 75) B X C: <0.001
p-value
Δ < 0.001 < 0.001 < 0.001
Δ Comparison of the PRISM scores between the follicular and luteal phases (Wilcoxon’s signed-rank test) within each treatment group.
* Comparison of the difference in PRISM score between the follicular and luteal phases among the three groups (Mann-Whitney test).
P25:1
st quartile.
P75:3
rd quartile.
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marital status and schooling of the patients, confirming
the validity of the randomization procedure.
Various diagnostic scales are available; however, the
PRISM calendar was selected as being one of the best
known and most widely used in clinical and epidemiolo-
gical studies on PMS [12]. It consists of 23 questions on
symptoms and their intensity during the menstrual cycle
and is compatible with the criteria defined in the Diag-
nostic and Statistical Manual of Mental Disorders
(DSM-IV-TR). This self-applicable, relatively simple
questionnaire is adequate for evaluating large popula-
tions within a short period of time and allows quantifi-
cation of the symptoms reported by the patient and a
comparative analysis between individuals.
One of the strong points of the present study lies in
the rigorous inclusion criteria. If on the one hand these
stringent criteria made the admission of patients to the
study more difficult, on the other hand they contributed
by minimizing potential biases such as contraceptive
use, obesity, organic diseases or psychological disorders
that could have affected symptoms. The result was a rig-
orously selected sample population that was highly
motivated to participate in the study, so increasing the
internal validity of the study. This can be clearly seen
from the fact that none of the participants missed a visit
or abandoned treatment during the eight months of fol-
low-up. Only four patients were excluded from the ana-
lysis, one because she had hyperprolactinemia, which
was detected following admission to the study but
before initiating the study medication, a second because
of a thyroid disorder and the other two because they
were found to be in use of antidepressants that could
have hampered analysis of the results.
The use of the PRISM calendar in the first two
m o n t h so ff o l l o w - u ps e r v e dt oi d e n t i f yw o m e nw i t h
PMS and differentiate them from patients with psycho-
logical disorders, since in the latter group symptoms
do not improve at any time during the menstrual cycle.
In the period immediately preceding treatment, statisti-
cally significant differences were found in the overall
PRISM scores in the women in the three study groups
when the scores for the follicular phase of the cycle were
compared with the scores for the luteal phase, showing
that a significant increase in symptomatology did occur
within the same month, thus characterizing PMS.
A decrease in PRISM scores in both the follicular and
luteal phases was observed in all three groups, reflecting
an improvement in symptomatology. However, there
was a significant difference in the magnitude of the
reduction between the groups using the medication and
the placebo group. When the absolute difference
between the symptom score in the follicular and luteal
phases of each group was analyzed throughout the treat-
ment period, the groups were found to be paired with
respect to the difference in score points. Moreover, this
absolute difference, which reflects the intensity of PMS
symptoms within one single month, decreased gradually
in all three groups analyzed. However, there was a sta-
tistically significant difference between the groups using
either 1 or 2 grams of the medication and the placebo
group. This difference was already evident at three
months and became even more apparent after six
months of treatment. After only three months of treat-
ment, the effect of the medication on PMS symptoms
was already significant, whereas in the patients in the
placebo group this improvement was less noticeable.
Furthermore, after three months of treatment, clinical
improvement was bigger in the case of the women in
the 2-gram group compared to those in the 1-gram
group, showing that the higher dose of the essential
fatty acids contained in these pharmacological prepara-
tions resulted in a higher reduction in symptoms.
Analysis of the absolute and relative differences
between the overall symptom score in the follicular and
luteal phases of the cycle throughout the treatment per-
iod in the three groups evaluated showed that scores of
symptoms diminished significantly, both in the follicular
phase and in the luteal phase in groups A (1 gram of
medication) and B (2 grams of medication), while the
decrease in group C (the placebo group) was more dis-
crete. However, this decrease in scores of symptoms in
the placebo group after six months of treatment was no
longer statistically significant. These data support the
hypothesis that this medication effectively reduces PMS
symptoms [12,16,23].
The initial clinical improvement observed in patients
in group C (placebo) was probably due to the “placebo
effect”, an important factor that is widely recognized in
the literature and describes a phenomenon that occurs
when a clinical improvement is found in an effect under
analysis in a person or group in which the treatment
given was inert [24]. When dealing with PMS patients,
Table 3 Prolactin and total cholesterol levels (mean ± SD)
according to treatment group and evaluation moment
Measurement Serum Levels in Treatment Group p-value*
A (1 g) B (2 g) C (Placebo)
Prolactin
Baseline 7.54 ± 2.1 7.87 ± 2.5 8.24 ± 3.4
6 months 7.03 ± 1.7 7.75 ± 2.7 7.58 ± 3.5 0.3282
Total cholesterol
Baseline 178.8 ± 13.9 172.6 ± 28.1 180.2 ± 14.1
6 months 176.2 ± 14.3 177.1 ± 10.2 179.2 ± 14.8 0.3364
* Comparison of the relative variation (%) between groups (ANOVA).
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than in other situations, since, within the physiological
and pathological bases of this syndrome, the emotional
factor is of utmost importance. Patients with PMS are
generally vulnerable and distressed by their cyclic symp-
toms, which may be debilitating. Psychosocial manage-
ment is, therefore, essential and should involve the
interaction and education of family members, as well as
lifestyle changes and medication. Data from the litera-
ture show that an improvement of as much as 50% in
symptoms is found in up to 20% of patients submitted
to placebo treatment in PMS studies [24].
Many PMS symptoms are similar to the effect pro-
duced by an injection of prolactin [12,25]. Some women
with PMS have high prolactin levels; however, levels are
normal in the vast majority of patients. Women with
PMS may be abnormally sensitive to normal amounts of
prolactin [12] and this phenomenon may be associated
with low PGE1 levels.
This could be a consequence of the fact that PGE1
acts on almost all organs of the body. It has a diuretic
effect by promoting a reduction in angiotensin II. Fatty
acids from food intake alter hormone and neuropeptide
levels such as norepinephrine, dopamine and serotonin.
Fatty acids also affect receptors for hormones and neu-
ropeptides [26] and, through PGE1, affect tissue sensitiv-
ity to prolactin. There is evidence that prostaglandin E1
is able to attenuate the biological effects of prolactin
and that, in the absence of prostaglandin E1, the effects
of prolactin are exacerbated [16].
The results of this study confirm the findings of other
authors who have recommended polyunsaturated fatty
acids as a therapeutic option for patients with PMS
[12,20,22,23]. Many studies have shown the efficacy of
nutrients on PMS symptoms. Most report an improve-
ment, mainly in emotional symptoms, with the use of pyri-
doxine (vitamin B6) [27]. Ascorbic acid and niacin have
also been mentioned. Pyridoxine deficiency has already
been suggested as a cause of PMS [27,28]. Magnesium
hypoactivity has also been associated with different patho-
logical states such as PMS, since magnesium levels are clo-
sely related to the activity and secretion of gonadal
hormones and this may contribute towards the genesis of
this condition [29,30]. Nonetheless, the clinical success
obtained with some of these nutrients may be partially
related to their effects on essential fatty acid metabolism
and PGE1 production, since the delta-6 desaturase enzyme
requires the presence of zinc, magnesium and insulin to
exert its effect, while the formation of gamma-linolenic
and dihomo-gamma-linolenic acids requires pyridoxine as
a cofactor. On the other hand, COX-1 requires the pre-
sence of niacin, vitamin C and zinc.
Currently, serotonin reuptake inhibitors (5-HT) are
gaining popularity for the treatment of PMS, since
studies show that a deficiency of this substance may be
involved in the etiology of the condition [31]. Therefore,
serotonergic antidepressants such as sertraline, fluoxe-
tine, citalopram and clomipramine have been shown to
be effective for intermittent use in the luteal phase of
the menstrual cycle [32], mainly in patients with PMDD,
resulting in a reduction in emotional and physical symp-
toms. Studies have shown no differences on the effects
of this medication in the treatment of PMS, and particu-
larly PMDD, when use is continuous or restricted to the
luteal phase; therefore, intermittent use is recommended
[33-35].
To evaluate whether essential fatty acids would alter
prolactin levels by increasing PGE1 levels, this hormone
was measured during the luteal phase at the beginning
and at the end of treatment. When prolactin levels were
compared in the three groups evaluated over the six
months of treatment, no statistically significant differ-
ences were found between baseline values and levels
measured at the end of the treatment period, showing
that the medication had no direct effect on prolactin.
This reinforces the hypothesis that the improvement in
symptoms is probably due to alterations in tissue sensi-
tivity to this substance [12].
One concern when administering essential fatty acids
as a dietary supplement is their effect on lipid indexes.
To evaluate this effect, total cholesterol was measured
prior to and following treatment. No statistically signifi-
cant difference was found between the groups, or
between the evaluation moments during treatment,
showing that the administration of a dietary supplement
of essential fatty acids did not result in any changes in
total cholesterol in the patients evaluated.
These findings confirm results published in the litera-
ture showing that no hormonal or biochemical changes
occurred with the use of essential fatty acids in patients
with PMS [25].
Few adverse events were recorded and these were
mild, insignificant and did not appear to be directly
related to the medication. The two patients in the pla-
cebo group who suffered episodes of diarrhea may be
excessively sensitive to mineral oil, since the dose given
was too low to act as a laxative. Nevertheless, these
patients later reported having had no further episodes of
these symptoms.
Conclusions
The results of the current study present some evidence in
support of the use of essential fatty acids in PMS patients.
A significant improvement in symptoms was achieved in
the patients who used the medication containing the
active ingredient. The data also show that the administra-
tion of 2 grams of this substance, although resulting in a
higher clinical response, did not appear to affect the final
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medication for 6 months appears to result in a better
clinical improvement compared to the results found after
three months of treatment.
At the doses used in the study, the medication had no
significant effect on serum prolactin levels. This rein-
forces the hypothesis that its effects on PMS symptoms
are the result of its interaction with prolactin receptors
through the action of prostaglandin E1 whose metabo-
lism is directly affected by essential fatty acid levels. At
the doses used and within the duration of this study, the
essential fatty acid preparations did not result in any sig-
nificant changes in total cholesterol levels in previously
healthy patients.
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